Must-Listen Interview: Lior Rauchberger on the Future of Digital Health & Personalized Medicine!

By Gene by Gene

Must-Listen Interview: Lior Rauchberger on the Future of Digital Health & Personalized Medicine!

Excited to share this interview with our CEO, Lior Rauchberger, providing insights into the rapidly evolving healthcare landscape.

Contact us for Media Inquires

Thank you!

Your submission has been received. Our laboratory will be in touch soon to follow up your enquiry.

An error occurred while submitting the form. Please try again. If the issue persists, please contact our support team.

More Gene by Gene Company News

Gene by Gene Appoints Brent Manning as Chief Operating Officer

Gene by Gene today announced the promotion of Brent Manning to Chief Operating Officer (COO), effective immediately. This appointment reflects Manning’s exceptional leadership, long-standing contributions, and critical role in driving the company’s continued growth and operational excellence.

Read Article >

Modernizing High-Throughput Workflows: A Case Study on Transitioning from Microarray to NGS

Microarrays built the foundation of high-throughput genotyping. Now, NGS is redefining it.

Read Article >

Next-Gen Sequencing Is Going Mainstream. What Does That Mean For You?

Genomics has evolved far beyond its early days of basic ancestry reports.

Read Article >

Gene by Gene CEO Reflects on Recent Progress in DNA Testing While at Precision Medicine World Conference (PMWC 2026) in California’s Silicon Valley

Lior Rauchberger, MD, CEO of Houston-based Gene by Gene and sister company Melbourne-based myDNA, was an attendee of the Precision Medicine World Conference (PMWC 2026) (March 4-6) and BioQuick News arranged to talk briefly with him about the progress of his companies shortly after he arrived in Silicon Valley from his home in Australia for the PMWC meeting.

Read Article >

Ultima Genomics Launches New Generation High-Throughput Sequencers, Emulsion PCR-Free Amplification

Ultima Genomics on Monday launched the UG200 series of high-throughput sequencers, a new generation of the company's platform that, paired with the new Solaris 2.0 chemistry and workflow, promises a smaller footprint, faster run times, higher output, as well as improved usability and flexibility.

Read Article >